StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

Equities research analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Monday. The firm set a “hold” rating on the stock.

Separately, JMP Securities reissued a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Price Performance

DBV Technologies stock opened at $7.14 on Monday. The firm has a 50 day simple moving average of $4.87 and a 200-day simple moving average of $4.04. The stock has a market cap of $146.86 million, a price-to-earnings ratio of -1.59 and a beta of -0.08. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $8.50.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.